Viking is developing VK2735, its dual GIP/GLP-1 receptor agonist, in injectable form -- like current marketed weight treatments -- and it's also working on an oral version. The former is involved in a ...
Zacks Investment Research on MSN
Is Viking Therapeutics (VKTX) a Buy as Wall Street Analysts Look Optimistic?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about ...
Viking (NYSE:VIK) priced its secondary offering of an aggregate of ~30.53M ordinary shares at a public offering price of $44.20 per share. The offering is expected to close on May 29, 2025. The ...
(RTTNews) - Viking Holdings Ltd (VIK) announced the pricing of its secondary offering of an aggregate of about 30.53 million ordinary shares at a public offering price of $44.20 per share. The ...
Viking Therapeutics is nearing the finish line with a candidate for weight loss -- to potentially enter a drug market that’s approaching $100 billion. This biotech has candidates in phase 2 and phase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback